NEW DRUG IN THE EVOLUTION OF LONG-ACTING INSULINS

Abstract

Insulin glargine, synthesized using recombinant DNA technology in a concentration of 100 U/ml, was the first once-daily longacting insulin analogue introduced into clinical practice in 2000. Glargin has a well-established record of efficacy and safety and is the most widely used insulin worldwide. In February 2015, the drug lost its US patent protection, which opened the door for biosimilar competitors.

Keywords

• diabetes mellitus
• insulin therapy
• long-acting insulin